|
|
Article: AVI BioPharma Drug Demonstrates Strong Survival Benefits and Elimination of Ebola Virus in Animals.
- Article from:
- Business Wire
- Article date:
- September 12, 2007
CopyrightCOPYRIGHT 2007 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Encouraging Results Also Shown Against Marburg Virus
PORTLAND, Ore. -- AVI BioPharma, Inc. (Nasdaq:AVII) announced today the presentation of data from two studies evaluating the company's NEUGENE([R]) PLUS therapeutic antisense compounds in the treatment of nonhuman primates (NHP) exposed to the Ebola virus. Results of the studies were presented at the National Institutes of Health's Filovirus Animal Workshop by Dr. Sina Bavari, principal investigator, U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID).
The studies were conducted in collaboration with USAMRIID and funded as part of AVI's two-year, $28 million research contract with ...